Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 11:35:e2410011.
doi: 10.4014/jmb.2410.10011.

Inhibitory Activity of Glycosides from Elsholtzia ciliata against Soluble Epoxide Hydrolase and Cytokines in RAW264.7 Cells

Affiliations

Inhibitory Activity of Glycosides from Elsholtzia ciliata against Soluble Epoxide Hydrolase and Cytokines in RAW264.7 Cells

Jang Hoon Kim et al. J Microbiol Biotechnol. .

Abstract

Soluble epoxide hydrolase (sEH) and pro-inflammatory cytokines are associated with the development of inhibitors for cardiovascular and inflammatory diseases. Here, we report on four natural sEH inhibitors isolated from the aerial parts of Elsholtzia ciliata (Thunb.) Hyl.. The four compounds, 1-4, were identified as luteolin-7-O-glucoside (1), yuanhuanin (2), apigenin-7-O-glucoside (3), and butein-4'-O-glucoside (4). Among them, compounds 2 and 4 are reported for the first time from this plant. In vitro and in silico, they showed inhibitory activity towards sEH at micromole concentrations. Moreover, they suppressed pro-inflammatory cytokines in polyinosinic:polycytidylic acid (poly(I:C))-stimulated RAW264.7 cells. Notably, 4 significantly downregulated the sEH catalytic reaction, NO and PGE2 production, and the expression levels of iNOS, COX-2, IL-6 mRNA, and sEH mRNA. Therefore, butein-4'-O-glucoside (4) is a potential sEH inhibitor that may be suitable for treating inflammation and cardiovascular diseases caused by infection.

Keywords: Elsholtzia ciliata; Lamiaceae; cytokines; glycoside; soluble epoxide hydrolase.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

The authors have no financial conflicts of interest to declare.

Figures

Fig. 1
Fig. 1. The structure of compounds 1–4 derived from the aerial parts of E. ciliata.
Fig. 2
Fig. 2. The inhibitory activity (A), Lineweaver-burk (B–E) and Dixon (F–I) plots of compounds 1–4 toward sEH.
Fig. 3
Fig. 3. The hydrogen bonds of inhibitors 1–4 (A–D) with sEH.
The overlapped pose of inhibitor 4 (E) with sEH for 100 ns (red: 0 ns, orange: 10 ns, yellow: 20 ns, green: 30 ns, cyan: 40 ns, blue: 50 ns, conflower blue: 60 ns, purple: 70 ns, menganta: 80 ns, white: 90 ns, black: 100 ns). RMSD (F), RMSF (G), the potential energy (H), and hydrogen bonds (I) of the simulation.
Fig. 4
Fig. 4. Cell viability of inhibitors on RAW264.7 cells (A).
The inhibitory activity of inhibitors 14 on NO (B) and PGE2 (C) production in poly (I.C.)-stimulated RAW264.7 cells. iNOS and COX-2 protein levels (D) in western blot and relative densities iNOS (E) and COX-2 (F) of by inhibitors. IL-6 (G) protein levels, and IL-6 (H) and sEH (I) mRNA expression levels.

Similar articles

References

    1. World Health Organization, author. Cardiovascular diseases(CVDs) [Accessed March 13, 2024]. Available from. https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases...
    1. Tu R, Armstrong J, Lee KSS, Hammock BD, Sapirstein A, Koehler RC. Soluble epoxide hydrolase inhibition decreases reperfusion injury after focal cerebral ischemia. Sci. Rep. 2018;8:5279. doi: 10.1038/s41598-018-23504-1. - DOI - PMC - PubMed
    1. Imig JD, Hammock BD. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat. Rev. 2009;8:794–805. doi: 10.1038/nrd2875. - DOI - PMC - PubMed
    1. Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, et al. Anti-inflammatory properties of cytocherome 450 epoxygenasederived eicosanodis. Science. 1999;285:1276–1279. doi: 10.1126/science.285.5431.1276. - DOI - PMC - PubMed
    1. Wagner KM, McReynolds CB, Schmidt WK, Hammock BD. Soluble epoxide hydrolase as a therapeutic target for pain, inflammatory and neurodegenerative diseases. Pharmacol. Ther. 2017;180:62–76. doi: 10.1016/j.pharmthera.2017.06.006. - DOI - PMC - PubMed

MeSH terms